BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rodrigues SG, Mendoza YP, Bosch J. Beta-blockers in cirrhosis: Evidence-based indications and limitations. JHEP Rep 2020;2:100063. [PMID: 32039404 DOI: 10.1016/j.jhepr.2019.12.001] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 19.5] [Reference Citation Analysis]
Number Citing Articles
1 Fallahzadeh MA, Asrani SK, Tapper EB, Saracino G, Rahimi RS. Nonselective beta-blocker use is associated with increased hepatic encephalopathy-related readmissions in cirrhosis. World J Clin Cases 2022; 10(23): 8097-8106 [DOI: 10.12998/wjcc.v10.i23.8097] [Reference Citation Analysis]
2 Chauhan A, Bhatia A. Letter: non-selective beta-blockers in cirrhosis-effect beyond portal hypertension. Aliment Pharmacol Ther 2022;56:184-5. [PMID: 35689323 DOI: 10.1111/apt.16941] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Singh V, Kumar P, Verma N, Vijayvergiya R, Singh A, Bhalla A. Propranolol vs. band ligation for primary prophylaxis of variceal hemorrhage in cirrhotic patients with ascites: a randomized controlled trial. Hepatol Int. [DOI: 10.1007/s12072-022-10361-4] [Reference Citation Analysis]
4 Mao G, Li C, Wang H, Jv YH, Zhang Y, Liu L, Tang M. Exploration on the Effect of Nonselective β-Receptor Blockers (NSBBs) on Hemodynamic Parameters in Complicated Liver Cirrhosis. BioMed Research International 2022;2022:1-8. [DOI: 10.1155/2022/7922906] [Reference Citation Analysis]
5 Kulkarni AV, Anand AC. Non-invasive tests, Portal hypertension, and Beta-blockers: A step towards a greener environment! Journal of Clinical and Experimental Hepatology 2022. [DOI: 10.1016/j.jceh.2022.03.011] [Reference Citation Analysis]
6 Lashen SA, Shamseya MM, Madkour MA, Abdel Salam RM, Mostafa SS. β-arrestin-2 predicts the clinical response to β-blockers in cirrhotic portal hypertension patients: A prospective study. World J Hepatol 2022; 14(2): 429-441 [DOI: 10.4254/wjh.v14.i2.429] [Reference Citation Analysis]
7 Tranah TH, Kronsten VT, Shawcross DL. Implications and Management of Cirrhosis-Associated Immune Dysfunction Before and After Liver Transplantation. Liver Transpl 2021. [PMID: 34738724 DOI: 10.1002/lt.26353] [Reference Citation Analysis]
8 Zaccherini G, Tufoni M, Bernardi M, Caraceni P. Prevention of Cirrhosis Complications: Looking for Potential Disease Modifying Agents. J Clin Med 2021;10:4590. [PMID: 34640608 DOI: 10.3390/jcm10194590] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Wijarnpreecha K, Li F, Dang Y, Taner CB, Yang L, Tao C. Letter: hepatocellular carcinoma risk in patients with non-selective beta blockers-authors' reply. Aliment Pharmacol Ther 2021;54:1095-6. [PMID: 34564885 DOI: 10.1111/apt.16598] [Reference Citation Analysis]
10 Desai MS. Mechanistic insights into the pathophysiology of cirrhotic cardiomyopathy. Anal Biochem 2021;:114388. [PMID: 34587512 DOI: 10.1016/j.ab.2021.114388] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Marynissen H, Lodeweyckx T, Bielen D, de Hoon J. Doppler ultrasound to assess the pharmacodynamic effects of splanchnic vasoactive compounds. Br J Clin Pharmacol 2021. [PMID: 34558102 DOI: 10.1111/bcp.15095] [Reference Citation Analysis]
12 Tarasconi A, Perrone G, Davies J, Coimbra R, Moore E, Azzaroli F, Abongwa H, De Simone B, Gallo G, Rossi G, Abu-Zidan F, Agnoletti V, de'Angelis G, de'Angelis N, Ansaloni L, Baiocchi GL, Carcoforo P, Ceresoli M, Chichom-Mefire A, Di Saverio S, Gaiani F, Giuffrida M, Hecker A, Inaba K, Kelly M, Kirkpatrick A, Kluger Y, Leppäniemi A, Litvin A, Ordoñez C, Pattonieri V, Peitzman A, Pikoulis M, Sakakushev B, Sartelli M, Shelat V, Tan E, Testini M, Velmahos G, Wani I, Weber D, Biffl W, Coccolini F, Catena F. Anorectal emergencies: WSES-AAST guidelines. World J Emerg Surg 2021;16:48. [PMID: 34530908 DOI: 10.1186/s13017-021-00384-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
13 Kalo E, Read S, Ahlenstiel G. Targeting Gut–Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension. Livers 2021;1:147-79. [DOI: 10.3390/livers1030014] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
14 Wijarnpreecha K, Li F, Taner CB, Yang L, Tao C. Editorial: when to start carvedilol in cirrhosis-time to reconsider? Authors' reply. Aliment Pharmacol Ther 2021;54:728-9. [PMID: 34379839 DOI: 10.1111/apt.16526] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Jachs M, Hartl L, Schaufler D, Desbalmes C, Simbrunner B, Eigenbauer E, Bauer DJM, Paternostro R, Schwabl P, Scheiner B, Bucsics T, Stättermayer AF, Pinter M, Trauner M, Mandorfer M, Reiberger T. Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes. Gut 2021;70:1758-67. [PMID: 33199442 DOI: 10.1136/gutjnl-2020-322712] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 19.0] [Reference Citation Analysis]
16 Wijarnpreecha K, Li F, Xiang Y, Xu X, Zhu C, Maroufy V, Wang Q, Tao W, Dang Y, Pham HA, Zhou Y, Li J, Zhang X, Xu H, Taner CB, Yang L, Tao C. Nonselective beta-blockers are associated with a lower risk of hepatocellular carcinoma among cirrhotic patients in the United States. Aliment Pharmacol Ther 2021;54:481-92. [PMID: 34224163 DOI: 10.1111/apt.16490] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
17 Caraceni P, Abraldes JG, Ginès P, Newsome PN, Sarin SK. The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery. J Hepatol 2021;75 Suppl 1:S118-34. [PMID: 34039483 DOI: 10.1016/j.jhep.2021.01.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
18 Bernal W, Karvellas C, Saliba F, Saner FH, Meersseman P. Intensive care management of acute-on-chronic liver failure. J Hepatol 2021;75 Suppl 1:S163-77. [PMID: 34039487 DOI: 10.1016/j.jhep.2020.10.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Garcia-Pagan JC, Francoz C, Montagnese S, Senzolo M, Mookerjee RP. Management of the major complications of cirrhosis: Beyond guidelines. J Hepatol 2021;75 Suppl 1:S135-46. [PMID: 34039484 DOI: 10.1016/j.jhep.2021.01.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
20 Waguri N, Osaki A, Watanabe Y. Balloon-occluded retrograde transvenous obliteration for treatment of gastric varices. World J Hepatol 2021; 13(6): 650-661 [PMID: 34239700 DOI: 10.4254/wjh.v13.i6.650] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
21 Al-Dury S, Molinaro A, Hedenström P. Propranolol-induced hallucinations mimicking encephalopathy in a patient with liver cirrhosis. Scand J Gastroenterol 2021;56:829-31. [PMID: 33961526 DOI: 10.1080/00365521.2021.1919198] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Putera M, Teh KB, Kumar R, Wong YJ. Small esophageal varices in compensated cirrhosis patients: to treat or not to treat? J Hepatol 2021;75:491-2. [PMID: 33716090 DOI: 10.1016/j.jhep.2021.03.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
23 Alqahtani SA, Jang S. Pathophysiology and Management of Variceal Bleeding. Drugs 2021;81:647-67. [PMID: 33710585 DOI: 10.1007/s40265-021-01493-2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
24 Ishikawa T, Sasaki R, Nishimura T, Matsuda T, Iwamoto T, Saeki I, Hidaka I, Takami T, Sakaida I. Splenic non-infarction volume determines a clinically significant hepatic venous pressure gradient response to partial splenic embolization in patients with cirrhosis and hypersplenism. J Gastroenterol 2021;56:382-94. [PMID: 33629147 DOI: 10.1007/s00535-021-01762-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Mu X, Winsor W, Trahey J. Use of Non-Selective Beta-Blocker for Refractory Stomal Variceal Hemorrhage. Case Rep Gastroenterol 2021;15:87-91. [PMID: 33613168 DOI: 10.1159/000510921] [Reference Citation Analysis]
26 Guixé-muntet S, Zhu C, Xie W, Gracia-sancho J. Novel therapeutics for portal hypertension and fibrosis in chronic liver disease. Pharmacology & Therapeutics 2020;215:107626. [DOI: 10.1016/j.pharmthera.2020.107626] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
27 Calès P, Bertrais S, Boursier J, Fouchard I, Oberti F; SNIFF 16 group. Non-selective beta-blockers increase overall and liver mortality in alcoholic cirrhosis with MELD ≥ 12 over 5 years of follow-up. Liver Int 2021;41:168-79. [PMID: 32979020 DOI: 10.1111/liv.14674] [Reference Citation Analysis]
28 Kreisel W, Schaffner D, Lazaro A, Trebicka J, Merfort I, Schmitt-Graeff A, Deibert P. Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension. Int J Mol Sci 2020;21:E6223. [PMID: 32872119 DOI: 10.3390/ijms21176223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
29 Ishikawa T, Hamamoto K, Sasaki R, Nishimura T, Matsuda T, Iwamoto T, Takami T, Sakaida I. Significant improvement in portal‐systemic liver failure symptoms and successful management of portal‐splenic venous hemodynamics by the combination of interventional radiology and pharmacotherapy. Hepatol Res 2020;50:1201-8. [DOI: 10.1111/hepr.13545] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
30 Lotersztajn S. Happy 2020: JHEP Reports is starting its second year. JHEP Reports 2020;2:100079. [DOI: 10.1016/j.jhepr.2020.100079] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]